deferoxamine has been researched along with Neuroblastoma in 54 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based upon phase I and II studies of deferoxamine alone and in combination with cytotoxic agents cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT), we initiated a single arm multicentre trial in 1992 for advanced neuroblastoma." | 9.08 | Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. ( Bagnulo, S; Carli, M; Casale, F; De Bernardi, B; De Sio, L; Deb, G; Donfrancesco, A; Helson, L; Mancini, A; Nigro, M, 1995) |
| "The mechanisms of catechol-induced cytotoxicity were studied in cultures of neuroblastoma N2a cells." | 7.74 | Cytotoxic effects of catechol to neuroblastoma N2a cells. ( Alvarez, LD; Clarêncio, J; Costa, MF; Costa, SL; El-Bachá, RS; Lima, RM, 2008) |
| "A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed." | 7.68 | Effects of a single course of deferoxamine in neuroblastoma patients. ( Castello, MA; Deb, G; Dominici, C; Donfrancesco, A; Helson, L; Pileggi, D, 1990) |
| "Deferoxamine previously has been shown to have potent activity in vitro against human neuroblastoma cells, activity that results from its ability to chelate iron." | 7.67 | Mechanism of antineuroblastoma activity of deferoxamine in vitro. ( Blatt, J; Stitely, S; Taylor, SR, 1988) |
| "The iron chelator, deferoxamine, has demonstrated cytotoxicity against neuroblastoma cells." | 7.67 | Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. ( Blatt, J; Kontoghiorghes, GJ; Taylor, SR, 1989) |
| "Patients with widespread neuroblastoma (NB) frequently have elevated serum ferritin levels, and recently anti-NB effects of the iron chelator deferoxamine (DFO) have been reported." | 7.67 | Deferoxamine inhibition of human neuroblastoma viability and proliferation. ( Becton, DL; Bryles, P, 1988) |
| "In view of the high relapse rate following chemotherapy for patients with advanced neuroblastoma (NB) and primitive neuroectodermal tumors (PNET), we designed a novel chemotherapy program which incorporated the iron chelator deferoxamine." | 5.07 | D-CECaT: a breakthrough for patients with neuroblastoma. ( Angioni, A; Boglino, C; Cozza, R; Deb, G; Donfrancesco, A; Helson, L; Jenkner, A; Landolfo, A; Maurizio, C, 1993) |
| "The mechanisms of catechol-induced cytotoxicity were studied in cultures of neuroblastoma N2a cells." | 3.74 | Cytotoxic effects of catechol to neuroblastoma N2a cells. ( Alvarez, LD; Clarêncio, J; Costa, MF; Costa, SL; El-Bachá, RS; Lima, RM, 2008) |
| "CHP212 neuroblastoma cells were exposed to two different nitric oxide (NO) donors, S-nitroso-N-acetylpenicillamine and sodium nitroprusside." | 3.70 | S-nitroso-N-acetylpenicillamine and nitroprusside induce apoptosis in a neuronal cell line by the production of different reactive molecules. ( Nieland, LJ; Ramaekers, FC; Reutelingsperger, CP; Schutte, B; Steinbusch, HW; Terwel, D, 2000) |
| "Deferoxamine (DFO) caused decreased viability of human neuronal tumor cells (SK-N-MC neuroblastoma and U-373 MG astrocytoma) in a dose-dependent manner." | 3.69 | Deferoxamine-induced cytotoxicity in human neuronal cell lines: protection by free radical scavengers. ( Lee, YS; Wurster, RD, 1995) |
| "The mechanisms of iron uptake from transferrin and the effects of iron chelators on these processes were investigated in human neuroblastoma cells." | 3.69 | The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. ( Ponka, P; Richardson, DR, 1994) |
| "Intracellular iron deprivation by deferoxamine treatment, which leads to cells arrest in the S phase, enhanced c-fos expression in the neuroblastoma cell line, IMR32." | 3.68 | Enhanced c-fos expression after intracellular iron deprivation. ( Fukuchi, K; Gomi, K; Takagi, Y; Tomoyasu, S; Tsuruoka, N; Watanabe, H; Watanabe, K, 1993) |
| "A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed." | 3.68 | Effects of a single course of deferoxamine in neuroblastoma patients. ( Castello, MA; Deb, G; Dominici, C; Donfrancesco, A; Helson, L; Pileggi, D, 1990) |
| "Deferoxamine previously has been shown to have potent activity in vitro against human neuroblastoma cells, activity that results from its ability to chelate iron." | 3.67 | Mechanism of antineuroblastoma activity of deferoxamine in vitro. ( Blatt, J; Stitely, S; Taylor, SR, 1988) |
| "The iron chelator, deferoxamine, has demonstrated cytotoxicity against neuroblastoma cells." | 3.67 | Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. ( Blatt, J; Kontoghiorghes, GJ; Taylor, SR, 1989) |
| " Iron is an essential nutrient but high levels are toxic due to the catalytic generation of destructive hydroxyl radicals." | 1.43 | A role for amyloid precursor protein translation to restore iron homeostasis and ameliorate lead (Pb) neurotoxicity. ( Cahill, CM; Jiang, H; Liu, Y; Rogers, JT; Smith, A; Tummala, V; Venkataramani, V; Washburn, C, 2016) |
| "Our results demonstrate that scrapie infection leads to changes in cellular iron metabolism, affecting both total cellular and cytosolic free iron, and the activities and expression of major regulators of cellular iron homeostasis." | 1.33 | Changed iron regulation in scrapie-infected neuroblastoma cells. ( Bedecs, K; Fernaeus, S; Hälldin, J; Land, T, 2005) |
| "Phenserine was most efficient to block translation under conditions of intracellular iron chelation with desferrioxamine suggesting that this anticholinesterase operated through an iron (metal)-dependent pathway at the APP 5'-UTR site." | 1.32 | The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. ( Bush, AI; Eder, P; Giordano, T; Greig, NH; Lahiri, DK; Rogers, JT; Venti, A, 2004) |
| "Neuroblastoma is the second most common solid malignancy of childhood." | 1.31 | Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. ( Berg, PE; Eskenazi, AE; Fan, L; Frantz, CN; Frick, KK; Ikegaki, N; Iyer, J; Kennett, RH; Wada, RK; Zhu, S, 2001) |
| " Hydrogen peroxide would be converted to more toxic hydroxyl free radicals." | 1.30 | Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. ( Lai, CT; Yu, PH, 1997) |
| "We tested non-hematopoietic human tumors for in vitro sensitivity to either a pair of synergistic IgG antitransferrin (Tf) receptor monoclonal antibodies (MAbs), deferoxamine (DFO) or the combination thereof." | 1.29 | Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. ( Kemp, JD; Kovar, J; Naumann, PW; Stewart, BC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (11.11) | 18.7374 |
| 1990's | 18 (33.33) | 18.2507 |
| 2000's | 22 (40.74) | 29.6817 |
| 2010's | 7 (12.96) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Rakshit, J | 1 |
| Priyam, A | 1 |
| Gowrishetty, KK | 1 |
| Mishra, S | 1 |
| Bandyopadhyay, J | 1 |
| Guo, C | 1 |
| Hao, LJ | 1 |
| Yang, ZH | 1 |
| Chai, R | 1 |
| Zhang, S | 1 |
| Gu, Y | 1 |
| Gao, HL | 1 |
| Zhong, ML | 1 |
| Wang, T | 1 |
| Li, JY | 1 |
| Wang, ZY | 1 |
| Rogers, JT | 3 |
| Venkataramani, V | 1 |
| Washburn, C | 1 |
| Liu, Y | 1 |
| Tummala, V | 1 |
| Jiang, H | 1 |
| Smith, A | 1 |
| Cahill, CM | 1 |
| Babcock, J | 1 |
| Herrera, A | 1 |
| Coricor, G | 1 |
| Karch, C | 1 |
| Liu, AH | 1 |
| Rivera-Gines, A | 1 |
| Ko, JL | 1 |
| Guan, H | 1 |
| Yang, H | 1 |
| Yang, M | 1 |
| Yanagisawa, D | 1 |
| Bellier, JP | 1 |
| Mori, M | 1 |
| Takahata, S | 1 |
| Nonaka, T | 1 |
| Zhao, S | 1 |
| Tooyama, I | 1 |
| Puppo, M | 1 |
| Battaglia, F | 1 |
| Ottaviano, C | 1 |
| Delfino, S | 1 |
| Ribatti, D | 1 |
| Varesio, L | 2 |
| Bosco, MC | 2 |
| Nevo, I | 1 |
| Sagi-Assif, O | 1 |
| Edry Botzer, L | 1 |
| Amar, D | 1 |
| Maman, S | 1 |
| Kariv, N | 1 |
| Leider-Trejo, LE | 1 |
| Savelyeva, L | 1 |
| Schwab, M | 1 |
| Yron, I | 1 |
| Witz, IP | 1 |
| Gulyani, S | 1 |
| Earley, CJ | 1 |
| Camandola, S | 1 |
| Maudsley, S | 1 |
| Ferré, S | 1 |
| Mughal, MR | 1 |
| Martin, B | 1 |
| Cheng, A | 1 |
| Gleichmann, M | 1 |
| Jones, BC | 2 |
| Allen, RP | 1 |
| Mattson, MP | 1 |
| Guo, S | 1 |
| Miyake, M | 1 |
| Liu, KJ | 1 |
| Shi, H | 1 |
| Lima, RM | 1 |
| Alvarez, LD | 1 |
| Costa, MF | 1 |
| Costa, SL | 1 |
| Clarêncio, J | 1 |
| El-Bachá, RS | 1 |
| Mitchell, RM | 1 |
| Lee, SY | 1 |
| Simmons, Z | 1 |
| Connor, JR | 1 |
| Hegde, NV | 1 |
| Jensen, GL | 1 |
| Unger, EL | 2 |
| Castino, R | 2 |
| Fiorentino, I | 1 |
| Cagnin, M | 1 |
| Giovia, A | 1 |
| Isidoro, C | 2 |
| Rapella, A | 1 |
| Negrioli, A | 1 |
| Melillo, G | 1 |
| Pastorino, S | 1 |
| Watts, RN | 1 |
| Richardson, DR | 2 |
| Sangchot, P | 1 |
| Sharma, S | 1 |
| Chetsawang, B | 1 |
| Porter, J | 1 |
| Govitrapong, P | 1 |
| Ebadi, M | 1 |
| Venti, A | 1 |
| Giordano, T | 1 |
| Eder, P | 1 |
| Bush, AI | 2 |
| Lahiri, DK | 1 |
| Greig, NH | 2 |
| Fernaeus, S | 1 |
| Hälldin, J | 1 |
| Bedecs, K | 1 |
| Land, T | 1 |
| Callinan, L | 1 |
| McCarthy, TV | 1 |
| Maulet, Y | 1 |
| Mackrill, JJ | 1 |
| Shamoto-Nagai, M | 1 |
| Maruyama, W | 1 |
| Yi, H | 1 |
| Akao, Y | 1 |
| Tribl, F | 1 |
| Gerlach, M | 1 |
| Osawa, T | 1 |
| Riederer, P | 1 |
| Naoi, M | 1 |
| Reznichenko, L | 1 |
| Amit, T | 1 |
| Zheng, H | 1 |
| Avramovich-Tirosh, Y | 1 |
| Youdim, MB | 2 |
| Weinreb, O | 1 |
| Mandel, S | 1 |
| Wiesinger, JA | 1 |
| Buwen, JP | 1 |
| Cifelli, CJ | 1 |
| Beard, JL | 1 |
| Bellio, N | 1 |
| Nicotra, G | 1 |
| Follo, C | 1 |
| Trincheri, NF | 1 |
| Bandyopadhyay, S | 1 |
| Huang, X | 1 |
| Cho, H | 1 |
| Donfrancesco, A | 5 |
| De Bernardi, B | 1 |
| Carli, M | 1 |
| Mancini, A | 1 |
| Nigro, M | 1 |
| De Sio, L | 3 |
| Casale, F | 1 |
| Bagnulo, S | 1 |
| Helson, L | 5 |
| Deb, G | 5 |
| Lee, YS | 1 |
| Wurster, RD | 1 |
| Ponka, P | 1 |
| Braverman, S | 1 |
| Mangiardi, J | 1 |
| Brodie, C | 1 |
| Siriwardana, G | 1 |
| Lucas, J | 1 |
| Schleicher, R | 1 |
| Terada, N | 1 |
| Szepesi, A | 1 |
| Gelfand, E | 1 |
| Seligman, P | 1 |
| Uney, JB | 1 |
| Anderton, BH | 1 |
| Thomas, SM | 1 |
| Angioni, A | 2 |
| Maurizio, C | 1 |
| Cozza, R | 2 |
| Jenkner, A | 1 |
| Landolfo, A | 1 |
| Boglino, C | 1 |
| Fukuchi, K | 1 |
| Tomoyasu, S | 1 |
| Watanabe, K | 1 |
| Watanabe, H | 1 |
| Takagi, Y | 1 |
| Tsuruoka, N | 1 |
| Gomi, K | 1 |
| Kovar, J | 1 |
| Naumann, PW | 1 |
| Stewart, BC | 1 |
| Kemp, JD | 1 |
| Castellano, A | 1 |
| Renton, FJ | 1 |
| Jeitner, TM | 1 |
| Lai, CT | 1 |
| Yu, PH | 1 |
| Hrubá, A | 1 |
| Skala, JP | 2 |
| Matĕjcková, S | 1 |
| Fales, I | 1 |
| Vodvárková, S | 1 |
| Starý, J | 1 |
| Kavan, P | 1 |
| Kobylka, P | 1 |
| Selig, RA | 1 |
| White, L | 1 |
| Gramacho, C | 1 |
| Sterling-Levis, K | 1 |
| Fraser, IW | 1 |
| Naidoo, D | 1 |
| Terwel, D | 1 |
| Nieland, LJ | 1 |
| Schutte, B | 1 |
| Reutelingsperger, CP | 1 |
| Ramaekers, FC | 1 |
| Steinbusch, HW | 1 |
| Tjalkens, RB | 1 |
| Ewing, MM | 1 |
| Philbert, MA | 1 |
| Rottkamp, CA | 1 |
| Raina, AK | 1 |
| Zhu, X | 1 |
| Gaier, E | 1 |
| Atwood, CS | 1 |
| Chevion, M | 1 |
| Perry, G | 1 |
| Smith, MA | 1 |
| Fan, L | 1 |
| Iyer, J | 1 |
| Zhu, S | 1 |
| Frick, KK | 1 |
| Wada, RK | 1 |
| Eskenazi, AE | 1 |
| Berg, PE | 1 |
| Ikegaki, N | 1 |
| Kennett, RH | 1 |
| Frantz, CN | 1 |
| Kitamuro, T | 1 |
| Takahashi, K | 1 |
| Totsune, K | 1 |
| Nakayama, M | 1 |
| Murakami, O | 1 |
| Hida, W | 1 |
| Shirato, K | 1 |
| Shibahara, S | 1 |
| Mizutani, A | 1 |
| Furukawa, T | 1 |
| Adachi, Y | 1 |
| Ikehara, S | 1 |
| Taketani, S | 1 |
| Rogers, PC | 1 |
| Chan, KW | 1 |
| Chao, HY | 1 |
| Rodriguez, WC | 1 |
| Dominici, C | 2 |
| Caniglia, M | 1 |
| Fidani, P | 1 |
| Amici, A | 1 |
| Weitman, SD | 1 |
| Buchanan, GR | 1 |
| Kamen, BA | 1 |
| Pileggi, D | 1 |
| Castello, MA | 1 |
| Blatt, J | 4 |
| Taylor, SR | 2 |
| Stitely, S | 2 |
| Kontoghiorghes, GJ | 1 |
| Huntley, D | 1 |
| Becton, DL | 1 |
| Bryles, P | 1 |
| Hill, BT | 1 |
| Whelan, RD | 1 |
| Hosking, LK | 1 |
1 review available for deferoxamine and Neuroblastoma
| Article | Year |
|---|---|
Role of deferoxamine in tumor therapy.
Topics: Antineoplastic Agents; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Neoplasms; Neur | 1996 |
2 trials available for deferoxamine and Neuroblastoma
| Article | Year |
|---|---|
Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chi | 1995 |
D-CECaT: a breakthrough for patients with neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Child; Child, Prescho | 1993 |
51 other studies available for deferoxamine and Neuroblastoma
| Article | Year |
|---|---|
Iron chelator Deferoxamine protects human neuroblastoma cell line SH-SY5Y from 6-Hydroxydopamine-induced apoptosis and autophagy dysfunction.
Topics: Apoptosis; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Survival; Deferoxamine; Humans; Immu | 2020 |
Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Death; Cell Line, Tumor; Deferoxamine; Disease | 2016 |
A role for amyloid precursor protein translation to restore iron homeostasis and ameliorate lead (Pb) neurotoxicity.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Deferoxamine; Gene Expression Regulation; Homeost | 2016 |
Mechanism Governing Human Kappa-Opioid Receptor Expression under Desferrioxamine-Induced Hypoxic Mimic Condition in Neuronal NMB Cells.
Topics: Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Adhesion; Cell Hypoxia; Cell L | 2017 |
Mitochondrial ferritin protects SH-SY5Y cells against H
Topics: alpha-Synuclein; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Line, Tumor; Deferoxa | 2017 |
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Lin | 2008 |
Generation and characterization of novel local and metastatic human neuroblastoma variants.
Topics: Adrenal Gland Neoplasms; Animals; Cell Line, Tumor; Cell Proliferation; Deferoxamine; Disease Models | 2008 |
Diminished iron concentrations increase adenosine A(2A) receptor levels in mouse striatum and cultured human neuroblastoma cells.
Topics: Adenosine; Animals; Cell Line, Tumor; Corpus Striatum; Cyclic AMP; Deferoxamine; Dose-Response Relat | 2009 |
Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment.
Topics: Analysis of Variance; Cell Death; Cell Hypoxia; Cell Line, Tumor; Deferoxamine; Enzyme-Linked Immuno | 2009 |
Cytotoxic effects of catechol to neuroblastoma N2a cells.
Topics: Animals; Antioxidants; Apoptosis; Ascorbic Acid; Catechols; Cell Line, Tumor; Cell Survival; Curcumi | 2008 |
HFE polymorphisms affect cellular glutamate regulation.
Topics: Analysis of Variance; Calcium; Cell Line, Tumor; Deferoxamine; Enzyme Inhibitors; Ferric Compounds; | 2011 |
Iron chelation down-regulates dopamine transporter expression by decreasing mRNA stability and increasing endocytosis in N2a cells.
Topics: Cell Line, Tumor; Deferoxamine; Dopamine Plasma Membrane Transport Proteins; Down-Regulation; Endocy | 2011 |
Chelation of lysosomal iron protects dopaminergic SH-SY5Y neuroblastoma cells from hydrogen peroxide toxicity by precluding autophagy and Akt dephosphorylation.
Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Deferoxami | 2011 |
Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma.
Topics: Antineoplastic Agents; Cell Hypoxia; Deferoxamine; Endothelial Growth Factors; Ferrous Compounds; Fl | 2002 |
The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Membrane Permeability; Cell-Free System; Cytosol; De | 2002 |
Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture.
Topics: Adenosine Triphosphate; alpha-Synuclein; Cell Survival; Deferoxamine; Ferric Compounds; Humans; Iron | 2002 |
The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region.
Topics: 5' Untranslated Regions; Amyloid beta-Protein Precursor; Cell Line, Tumor; Cholinesterase Inhibitors | 2004 |
Changed iron regulation in scrapie-infected neuroblastoma cells.
Topics: Animals; Blotting, Southern; Blotting, Western; Cell Line, Tumor; Deferoxamine; Electrophoretic Mobi | 2005 |
Atypical L-type channels are down-regulated in hypoxia.
Topics: Calcium Channels, L-Type; Cell Line, Tumor; Deferoxamine; Gene Expression Regulation; Humans; Hypoxi | 2005 |
Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome.
Topics: Acrolein; Analysis of Variance; Antioxidants; Blotting, Western; Brain; Cell Line, Tumor; Deferoxami | 2006 |
Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antigens, CD; Blotting, Western; Cat | 2006 |
Down-regulation of dopamine transporter by iron chelation in vitro is mediated by altered trafficking, not synthesis.
Topics: Animals; Biotinylation; Blotting, Western; Cell Line; Deferoxamine; Dopamine; Dopamine Plasma Membra | 2007 |
Cathepsin D-Bax death pathway in oxidative stressed neuroblastoma cells.
Topics: bcl-2-Associated X Protein; Cathepsin D; Cell Line, Tumor; Cell Survival; Deferoxamine; Humans; Hydr | 2007 |
Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator.
Topics: Amyloid beta-Protein Precursor; Cell Line, Tumor; Clioquinol; Deferoxamine; Dose-Response Relationsh | 2006 |
Deferoxamine-induced cytotoxicity in human neuronal cell lines: protection by free radical scavengers.
Topics: Analysis of Variance; Antioxidants; Astrocytoma; Calcium Channel Blockers; Cell Survival; Deferoxami | 1995 |
The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Topics: Deferoxamine; DNA; Humans; Iron; Iron Chelating Agents; Isoniazid; Neuroblastoma; Osmolar Concentrat | 1994 |
delta-Aminolevulinic acid effects on neuronal and glial tumor cell lines.
Topics: Aminolevulinic Acid; Cell Survival; Deferoxamine; Glioblastoma; Hemin; Humans; Nervous System Diseas | 1993 |
Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.
Topics: Aphidicolin; Cell Count; Cell Division; Deferoxamine; Drug Screening Assays, Antitumor; Ferritins; G | 1993 |
Changes in heat shock protein 70 and ubiquitin mRNA levels in C1300 N2A mouse neuroblastoma cells following treatment with iron.
Topics: Animals; Biological Transport; Blotting, Northern; Cell Survival; Deferoxamine; Heat-Shock Proteins; | 1993 |
Enhanced c-fos expression after intracellular iron deprivation.
Topics: Creatine Kinase; Cytosol; Deferoxamine; Gene Expression Regulation; Genes, fos; Iron; Neuroblastoma; | 1993 |
Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Deferoxamine; Down-Regulation; Female; Humans; Male; Neopl | 1995 |
Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Deferoxamine; Glioma; Humans; Iron Chelating Agent | 1996 |
Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors.
Topics: Ascorbic Acid; Catalase; Cell Survival; Deferoxamine; Dopamine; Levodopa; Lipid Peroxidation; Neurob | 1997 |
[Purging of hemopoietic progenitor cells in autologous transplantation].
Topics: Adult; Bone Marrow Purging; Child; Cyclophosphamide; Deferoxamine; Etoposide; Hematopoietic Stem Cel | 1997 |
Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
Topics: Administration, Oral; Animals; Child, Preschool; Deferiprone; Deferoxamine; Drug Delivery Systems; D | 1998 |
S-nitroso-N-acetylpenicillamine and nitroprusside induce apoptosis in a neuronal cell line by the production of different reactive molecules.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Catalase; Deferoxamine; Flow Cytometry; Hydrogen Peroxide; M | 2000 |
Differential cellular regulation of the mitochondrial permeability transition in an in vitro model of 1,3-dinitrobenzene-induced encephalopathy.
Topics: Adenosine Triphosphate; Antioxidants; bcl-2-Associated X Protein; bcl-X Protein; Brain Diseases; Cal | 2000 |
Redox-active iron mediates amyloid-beta toxicity.
Topics: Amyloid beta-Peptides; Antioxidants; Cell Death; Deferoxamine; Humans; Iron; Neuroblastoma; Neurons; | 2001 |
Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.
Topics: Aphidicolin; Apoptosis; Deferoxamine; Gene Expression; Gene Expression Regulation, Neoplastic; Genes | 2001 |
Differential expression of adrenomedullin and its receptor component, receptor activity modifying protein (RAMP) 2 during hypoxia in cultured human neuroblastoma cells.
Topics: Adrenomedullin; Antimutagenic Agents; Cell Hypoxia; Cobalt; Deferoxamine; Gene Expression; Humans; I | 2001 |
A zinc-finger protein, PLAGL2, induces the expression of a proapoptotic protein Nip3, leading to cellular apoptosis.
Topics: 3T3 Cells; Animals; Annexin A5; Apoptosis; Cell Hypoxia; Cell Membrane; Deferoxamine; DNA Probes; DN | 2002 |
Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Deferox | 1992 |
Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Chelation Therapy | 1992 |
Pulmonary toxicity of deferoxamine in children with advanced cancer.
Topics: Adolescent; Carcinoma, Renal Cell; Deferoxamine; Female; Humans; Infusions, Intravenous; Kidney Neop | 1991 |
Effects of a single course of deferoxamine in neuroblastoma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1990 |
Mechanism of antineuroblastoma activity of deferoxamine in vitro.
Topics: 2,2'-Dipyridyl; Cell Cycle; Cell Line; Cell Survival; Deferoxamine; DNA Replication; Humans; Neurobl | 1988 |
Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines.
Topics: Administration, Oral; Cell Cycle; Cell Survival; Deferiprone; Deferoxamine; Humans; Hydroxybenzoates | 1989 |
Enhancement of in vitro activity against neuroblastoma by doxorubicin and deferoxamine.
Topics: Cell Line; Cell Survival; Colorimetry; Deferoxamine; Dose-Response Relationship, Drug; Doxorubicin; | 1989 |
Deferoxamine inhibition of human neuroblastoma viability and proliferation.
Topics: Bone Marrow; Bone Marrow Cells; Cell Division; Cell Survival; Deferoxamine; Dose-Response Relationsh | 1988 |
Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening.
Topics: Antineoplastic Agents; Deferoxamine; Drug Screening Assays, Antitumor; Humans; Neuroblastoma; Sephar | 1988 |
Antineuroblastoma activity of desferoxamine in human cell lines.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Deferoxamine; Humans; Neuroblastoma | 1987 |